Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...

In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

The US Food and Drug Administration (FDA) has approved the first biosimilar form of omalizumab (Xolair) for the treatment of a range of allergic conditions. Omalizumab-igec (Omlyclo) is designed ...

The study of success eating food triggers after stopping Xolair is ongoing, so researchers are still collecting data for ...

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...

Omalizumab works by binding to the antibodies that promote allergic reactions, rendering them inactive, researchers said in background notes. The drug has been on the market since 2003 ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...